Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News

Welcome to the Cambridge Angels

Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News
Qkine and Enantis sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community
26 July 2021
Cambridge Angels
Qkine and Enantis sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community
Cambridge Angels
26 July 2021

Qkine and Enantis sign a licensing deal to bring hyperstable FGF2-STAB® to the global stem cell community

Cambridge Angels
26 July 2021

Source:https://qkine.com/2021/07/26/qkine-enantis-global-license-hyperstable-fgf2-stab-g3/

Newer PostPrivitar Expands Executive Leadership Team with Appointments of Victoria Normark as Chief Technology Officer, Pat Walsh as Chief Marketing Officer, and Bill Ziske as SVP of Sales North America
Older PostProjects funded to turn wastes into jet fuel
LI-In-Bug_small.png
Back to Top
Privacy
info@cambridgeangels.net